Coloplast Future Growth

Future criteria checks 4/6

Coloplast is forecast to grow earnings and revenue by 14.8% and 6.7% per annum respectively. EPS is expected to grow by 14.7% per annum. Return on equity is forecast to be 37.3% in 3 years.

Key information

14.8%

Earnings growth rate

14.71%

EPS growth rate

Medical Equipment earnings growth	16.0%
Revenue growth rate	6.7%
Future return on equity	37.32%
Analyst coverage	Good
Last updated	19 Dec 2025

Recent future growth updates

Coloplast A/S Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next

Aug 22

Recent updates

Coloplast (CPH:COLO B) Is Increasing Its Dividend To DKK18.00

Dec 04

Coloplast (CPH:COLO B) Will Pay A Larger Dividend Than Last Year At DKK18.00

Nov 20

Coloplast A/S Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next

Aug 22

An Intrinsic Calculation For Coloplast A/S (CPH:COLO B) Suggests It's 47% Undervalued

Jan 09

Operational Efficiencies And Innovations In Urology And Wound Care Propel Future Growth

Nov 07 Improved operational efficiency and strategic expansions are expected to enhance net margins and earnings over the long term.

Earnings and Revenue Growth Forecasts

CPSE:COLO B - Analysts future estimates and past financials data (DKK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2028	33,788	7,014	6,840	8,165	15
9/30/2027	31,435	6,398	5,999	7,270	18
9/30/2026	29,204	5,783	5,783	7,047	16
9/30/2025	27,874	3,636	5,218	6,645	N/A
6/30/2025	27,867	4,075	4,948	6,428	N/A
3/31/2025	27,794	4,544	4,873	6,287	N/A
12/31/2024	27,450	4,884	1,607	2,985	N/A
9/30/2024	27,030	5,052	1,420	2,766	N/A
6/30/2024	26,303	4,967	1,313	2,599	N/A
3/31/2024	25,526	4,965	1,053	2,278	N/A
12/31/2023	25,001	4,868	4,285	5,527	N/A
9/30/2023	24,500	4,783	2,985	4,226	N/A
6/30/2023	24,333	4,784	3,226	4,485	N/A
3/31/2023	24,074	4,801	3,663	4,894	N/A
12/31/2022	23,515	4,626	3,246	4,455	N/A
9/30/2022	22,579	4,706	3,964	5,099	N/A
6/30/2022	21,620	4,781	3,894	4,913	N/A
3/31/2022	20,606	4,746	3,735	4,712	N/A
12/31/2021	19,857	4,896	4,272	5,209	N/A
9/30/2021	19,426	4,825	3,324	5,290	N/A
6/30/2021	18,916	4,561	3,102	5,023	N/A
3/31/2021	18,500	4,304	3,162	5,077	N/A
12/31/2020	18,570	4,241	3,003	4,941	N/A
9/30/2020	18,544	4,197	3,828	4,759	N/A
6/30/2020	18,572	3,949	3,876	4,842	N/A
3/31/2020	18,752	4,020	3,872	4,764	N/A
12/31/2019	18,330	3,974	3,833	4,615	N/A
9/30/2019	17,939	3,873	3,667	4,357	N/A
6/30/2019	17,555	4,119	N/A	4,161	N/A
3/31/2019	17,181	3,999	N/A	4,177	N/A
12/31/2018	16,815	3,896	N/A	4,126	N/A
9/30/2018	16,449	3,845	N/A	4,361	N/A
6/30/2018	16,195	3,816	N/A	4,370	N/A
3/31/2018	15,882	3,778	N/A	4,111	N/A
12/31/2017	15,728	3,791	N/A	4,004	N/A
9/30/2017	15,528	3,797	N/A	3,251	N/A
6/30/2017	15,287	3,211	N/A	2,994	N/A
3/31/2017	15,061	3,279	N/A	2,492	N/A
12/31/2016	14,780	3,264	N/A	2,653	N/A
9/30/2016	14,681	3,143	N/A	3,028	N/A
6/30/2016	14,563	1,297	N/A	3,081	N/A
3/31/2016	14,417	1,028	N/A	3,568	N/A
12/31/2015	14,264	927	N/A	3,320	N/A
9/30/2015	13,909	899	N/A	3,337	N/A
6/30/2015	13,502	3,162	N/A	3,119	N/A
3/31/2015	13,096	3,241	N/A	3,015	N/A
12/31/2014	12,666	2,407	N/A	3,193	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: COLO B's forecast earnings growth (14.8% per year) is above the savings rate (1.7%).

Earnings vs Market: COLO B's earnings (14.8% per year) are forecast to grow faster than the Danish market (6.3% per year).

High Growth Earnings: COLO B's earnings are forecast to grow, but not significantly.

Revenue vs Market: COLO B's revenue (6.7% per year) is forecast to grow faster than the Danish market (4.6% per year).

High Growth Revenue: COLO B's revenue (6.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: COLO B's Return on Equity is forecast to be high in 3 years time (37.3%)

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/19 02:06
End of Day Share Price	2025/12/19 00:00
Earnings	2025/09/30
Annual Earnings	2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Coloplast A/S is covered by 38 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Hassan Al-Wakeel	Barclays
Robert Bate	Barclays

Coloplast Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Coloplast A/S Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next

Price target decreased by 7.5% to kr.752

Price target decreased by 8.0% to kr.827

Consensus EPS estimates fall by 15%

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Recent updates

Coloplast A/S Announces Executive Changes

Coloplast A/S Approves Interim Dividend for the Year 2025

Coloplast (CPH:COLO B) Is Increasing Its Dividend To DKK18.00

Coloplast (CPH:COLO B) Will Pay A Larger Dividend Than Last Year At DKK18.00

Less than half of directors are independent

Coloplast A/S Recommends Year-End Dividend

Coloplast A/S Announces Interim CEO Lars Rasmussen Will Step Down from the Board At the Upcoming Annual General Meeting on December 4, 2025

Coloplast A/S, Annual General Meeting, Dec 03, 2026

Coloplast A/S to Report Fiscal Year 2026 Results on Nov 05, 2026

Coloplast A/S Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

Investors Still Waiting For A Pull Back In Coloplast A/S (CPH:COLO B)

Price target decreased by 7.5% to kr.752

Price target decreased by 8.0% to kr.827

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

Coloplast A/S Announces CEO Changes

Does Coloplast (CPH:COLO B) Have A Healthy Balance Sheet?

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 35%?

Consensus EPS estimates fall by 15%

First quarter 2025 earnings: EPS misses analyst expectations

Coloplast A/S' (CPH:COLO B) Share Price Could Signal Some Risk

An Intrinsic Calculation For Coloplast A/S (CPH:COLO B) Suggests It's 47% Undervalued

An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B).

Upcoming dividend of kr.17.00 per share

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Operational Efficiencies And Innovations In Urology And Wound Care Propel Future Growth

Final dividend increased to kr.17.00

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

President & CEO exercised options and sold kr.5.0m worth of stock

Executive Vice President of Growth exercised options to buy kr.28m worth of stock.

Third quarter 2024 earnings: EPS misses analyst expectations

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

First half dividend of kr.5.00 announced

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Second quarter 2024 earnings: EPS misses analyst expectations

President & CEO exercised options and sold kr.13m worth of stock

First quarter 2024 earnings: Revenues in line with analyst expectations

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 20% undervalued after recent price drop

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources